FDA approves Novartis drug Afinitor for breast cancer

(Reuters) – The U.S. Food and Drug Administration on Friday approved Novartis AG drug Afinitor to treat women with a certain type of breast cancer. The drug is the first in a class known as mTOR inhibitors to be approved for post-menopausal women with advanced hormone-receptor positive, HER2-negative breast cancer. The European Medicines Agency in June also endorsed Afinitor as a breast cancer treatment. …